A subsequent molecular analysis performed for treatment purposes (and not par of our study) showed BRCA mutation, leading us to consider a diagnosis of high-grade serous carcinoma; however, this was excluded based on the low-grade nuclear atypia, the presence of squamous and morular differentiation, and the endometrioid-type immunophenotype (negativity for WT1, loss of PTEN expression, nuclear β-catenin accumulation) [31]. The gene discussed is WT1; the disease is serous adenocarcinoma.